AB-110 / Angiocrine, Yinfeng Biotechnology Group - LARVOL DELTA

Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells. (PubMed, Mol Oncol) - "It is derived from the ATR inhibitor VE-821 and recruits the E3 ubiquitin-ligase component cereblon to ATR...This mechanism provokes DNA replication catastrophe and augments anti-leukemic effects of the clinically used ribonucleotide reductase-2 inhibitor hydroxyurea...Treatment of wild-type but not of cereblon knockout cells with Abd110 stalls their proliferation which verifies that ATR elimination is the primary mechanism of Abd110. Altogether, our findings demonstrate specific anti-leukemic effects of an ATR PROTAC."

Journal • Ataxia • Hematological Malignancies • Immunology • Leukemia • Movement Disorders • Oncology • Primary Immunodeficiency • Targeted Protein Degradation • CRBN

COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS (CTOS 2023) - "Immunoprecipitation reactions were prepared using antibodies against the DUX4 CTD (abcam: ab124699), HA-epitope tag (abcam: ab9110), and H3K27ac (Active Motif 39134)... Identifying therapeutic vulnerabilities and novel treatment strategies necessitates a firm understanding of disease mechanisms. Because of its rare incidence, human tissues are not readily available however numerous cell lines containing the CIC-DUX4 gene fusion have been established; in some cases, unknowingly. Here we obtained these cell lines and used Next Generation Sequencing based approaches to comprehensively profile the transcriptional and chromatin landscape of CDS in human and mouse."

Preclinical • Ewing Sarcoma • Oncology • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Synovial Sarcoma • ACSL3 • CHEK2 • CIC • DUSP4 • DUSP6 • DUX4 • ETV1 • ETV4 • ETV5 • SHC3

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: Angiocrine Bioscience | Active, not recruiting ➔ Completed | Trial completion date: Nov 2022 ➔ Jan 2022

Trial completion • Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation (clinicaltrials.gov) - P1; N=10; Active, not recruiting; Sponsor: Angiocrine Bioscience; Trial completion date: Mar 2023 ➔ Nov 2022

Clinical • Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation (clinicaltrials.gov) - P1; N=10; Active, not recruiting; Sponsor: Angiocrine Bioscience; Recruiting ➔ Active, not recruiting; Trial completion date: Mar 2022 ➔ Mar 2023; Trial primary completion date: Jun 2020 ➔ Jun 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

Novel tetravalent bispecific T-cell engaging antibodies for cancer immunotherapy. (ASCO 2019) - "...In preclinical studies, ABP-100 was compared with a clinical-stage heterodimeric antibody that is monovalent for HER2 and CD3...ABP110 and ABP-150 also demonstrated potent cancer cell killing in vitro. This novel TetraBi antibody format enables concurrent bivalent and monovalent co-engagement of distinct target antigens in tumor microenvironment with promising therapeutic implications. Furthermore, it provides a potentially larger therapeutic index than more traditional bispecific formats that feature monovalent recognition of tumor antigens."

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Angiocrine Bioscience

Clinical • New P1 trial